Blog
RSS FeedPosted by Michael Wonder on 06 Jul 2022
U.S. Senate Democrats advance deal to lower drug prices
7 July 2022 - Democrats in the U.S. Senate are advancing a deal that would allow the government's Medicare health ...
Posted by Michael Wonder on 05 Jul 2022
Government drug price negotiations offer a false promise
5 July 2022 - With inflation rising and midterm elections just months away, Democrats are desperate for something they can ...
Posted by Michael Wonder on 04 Jul 2022
Report on 'Cell, Gene and Tissue Regulatory Framework in Australia: Stakeholder Perspectives' - TGA response
4 July 2022 - n November 2021 the TGA commissioned MTP Connect to conduct a stakeholder review of the regulatory ...
Posted by Michael Wonder on 04 Jul 2022
2022 October price disclosure cycle – indicative prices
4 July 2022 - Indicative 1 October 2022 prices resulting from the 2022 October Cycle of Price Disclosure have now been ...
Posted by Michael Wonder on 03 Jul 2022
Drug manufacturers are root cause of high drug costs; PBMs drive costs down
30 June 2022 - It should come as no surprise that pharmacy benefit managers applaud Congress for recent bipartisan action to ...
Posted by Michael Wonder on 03 Jul 2022
FTC goes after PBMs, warns of legal action
2 July 2022 - Last month, the Federal Trade Commission voted unanimously (5-0) to examine rising list prices of insulin, but ...
Posted by Michael Wonder on 03 Jul 2022
A key precedent may sustain negotiation to keep down Medicare drug prices
1 July 2022 - Medicare drug price negotiation, which holds down prices, may emerge from the long-quiet Senate negotiations on an ...
Posted by Michael Wonder on 03 Jul 2022
Drug prices make headlines again as Senate Democrats push forward pricing reforms
1 July 2022 - Senate Democrats appear to be making progress on pushing forward a set of politically popular drug pricing ...
Posted by Michael Wonder on 30 Jun 2022
From FDA to MHRA: are drug regulators for hire?
29.June 2022 - Patients and doctors expect drug regulators to provide an unbiased, rigorous assessment of investigational medicines before they hit ...
Posted by Michael Wonder on 28 Jun 2022
Fees and charges: summary from 1 July 2022
27 June 2022 - The TGA has updated its summary of fees and charges effective 1 July 2022. ...
Posted by Michael Wonder on 27 Jun 2022
Why won’t Congress do what Mark Cuban is doing for affordable drug prices?
27 June 2022 - You’ve probably heard of Mark Cuban, billionaire co-owner of the Dallas Mavericks, serial entrepreneur and investor, and ...
Posted by Michael Wonder on 26 Jun 2022
US seeks pharmaceutical deal with Switzerland to fast-track FDA approvals
27 June 2022 - The Biden administration wants to reach a narrow sectoral trade agreement with the Swiss pharmaceutical industry, ...
Posted by Michael Wonder on 26 Jun 2022
Price disclosure 2022 October cycle outcomes summary
24 June 2022 - The summary of price disclosure price reductions for the 2022 October Cycle has now been published on ...
Posted by Michael Wonder on 26 Jun 2022
Amryt to pursue formal dispute resolution for Oleogel-S10 (Filsuvez) NDA
24 June 2022 - Amryt today announces that the company plans to submit a formal dispute resolution request for the ...
Posted by Michael Wonder on 22 Jun 2022
BioMarin announces the Ministry of Health, Labor and Welfare in Japan granted approval for Voxzogo (vosoritide) for injection for the treatment of children with achondroplasia, whose growth plates are not closed
21 June 2022 - No lower age restriction for treatment. ...